MariTide Maridebart Cafraglutide
Amgen's once-monthly peptide-antibody conjugate that switches the GLP-1 receptor ON and the GIP receptor OFF, plus the real story behind the viral 'opposite mechanisms' claim.
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
How It Works
Two GLP-1 analog peptides are conjugated to the antibody and activate the GLP-1 receptor — curbing appetite and slowing gastric emptying, the same axis semaglutide and tirzepatide work through.
The IgG antibody backbone BLOCKS the GIP receptor instead of activating it. In preclinical and Phase 1 work this GIPR blockade added to GLP-1-driven weight loss.
Anchoring the GLP-1 peptides to a monoclonal antibody extends their half-life from minutes to weeks, enabling once-monthly (and in some trial arms once-every-8-weeks) subcutaneous dosing.
Tirzepatide ACTIVATES GIPR; MariTide BLOCKS it, yet both aid weight loss. Reviews note neither GIPR agonism nor antagonism alone shows a clear appetite effect in humans; each may work mainly by amplifying GLP-1 signaling. The mechanism is unresolved.
What the Data Shows
Key Takeaways
- MariTide (maridebart cafraglutide, formerly AMG 133) is Amgen's long-acting peptide-antibody conjugate: two GLP-1 receptor agonist peptides attached to a GIP-receptor-blocking antibody.
- In a 592-participant Phase 2 trial, once-monthly MariTide produced mean weight loss of −12.3% to −16.2% at 52 weeks in people with obesity, versus −2.5% on placebo.
- In participants with obesity AND type 2 diabetes, weight loss ranged −8.4% to −12.3%, versus −1.7% on placebo.
- The antibody backbone stretches the drug's half-life to weeks, enabling once-monthly (and in some arms once-every-8-weeks) subcutaneous dosing.
- Gastrointestinal side effects (nausea, vomiting) were common but less frequent when the dose was started low and escalated gradually.
- MariTide is in Phase 3 trials; it is NOT approved and NOT available for sale.
- Why GIPR ANTAGONISM (MariTide) and GIPR AGONISM (tirzepatide) both aid weight loss is unresolved. Reviewers note neither action alone produces a clear appetite effect in humans.
- The viral 'different brain circuits' explanation is a hypothesis, not an established finding: head-to-head mechanistic data in humans are lacking.
- Long-term (multi-year) efficacy, safety, and durability of weight loss beyond the trial windows are not yet known.
- MariTide has not been tested head-to-head against tirzepatide or retatrutide for total weight loss.
- Effects on cardiovascular outcomes, muscle preservation, and weight regain after stopping remain under investigation.
Frequently Asked Questions
What is MariTide (maridebart cafraglutide)?
MariTide is Amgen's investigational obesity drug — a peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor, given by subcutaneous injection roughly once a month. Formerly called AMG 133, it is in Phase 3 trials and not yet approved.
How much weight did people lose on MariTide?
In a Phase 2 trial of 592 people, those with obesity lost a mean of 12.3% to 16.2% of body weight at 52 weeks depending on dose, versus 2.5% on placebo. People with obesity and type 2 diabetes lost 8.4% to 12.3%, versus 1.7% on placebo.
How is MariTide different from Ozempic or Mounjaro?
Two ways. Dosing: MariTide's antibody backbone gives it a weeks-long half-life, allowing once-monthly injections instead of weekly. Mechanism: it BLOCKS the GIP receptor, whereas tirzepatide (Mounjaro/Zepbound) ACTIVATES it, while both also engage the GLP-1 receptor.
How can blocking GIPR and activating GIPR both cause weight loss?
This is a genuine open paradox. Current reviews suggest that in humans, neither GIPR agonism nor GIPR antagonism alone drives appetite loss — both approaches may work mainly by amplifying GLP-1 signaling. The 'different brain circuits' explanation circulating online is an unproven hypothesis, not settled science.
Is MariTide available to buy?
No. MariTide is an investigational Amgen drug in Phase 3 clinical trials — not approved or sold anywhere, and not available from research-chemical vendors. Be skeptical of any site claiming to sell it.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
MariTide is an investigational drug in clinical trials — not FDA-approved and not available for purchase.
Always consult a qualified healthcare provider before starting any weight-management therapy.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.